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Abstract 
Background: Non-Hodgkin lymphoma (NHL) continues to be the most common AIDS defining condition in the 
era of antiretroviral therapy. Whether chronic hepatitis B and C infection (HBV, HCV) promotes NHL in HIV 
infection is unclear. 
Objective: To investigate whether chronic HBV and HCV is associated with increased incidence of NHL in HIV 
infection. 
Design: Cohort study. 
Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe 
(COHERE). 
Patients: HIV infected patients with information on HBV surface antigen measurements and detectable HCV 
RNA or positive HCV antibodies if HCV RNA was not available. 
Measurements: Time dependent Cox models to assess the risk of NHL in patients remaining naïve and after 
start of antiretroviral therapy with inverse probability weighing to control for informative censoring. 
Results: We included 52,479 antiretroviral therapy-naïve patients (1339 (3.3%) with chronic HBV and 7506 
(18.7%) with HCV), of which 40,219 (77%) then went on to start antiretroviral therapy. The median follow up 
was 13 months for naïve and 50 months for patients on antiretroviral therapy. 252 -naïve and 310 treated 
patients developed NHL, with incidence rates of 219 and 168 per 100,000 person-years. The hazard ratio of 
NHL with HBV and HCV was 1.33 (95% CI 0.69, 2.56) and 0.67 (0.40, 1.12) in naïve patients and 1.74 (1.08, 
2.82) and 1.73 (1.21, 2.46) in antiretroviral therapy -treated patients, respectively. 
Limitations: Many naïve patients initiated antiretroviral therapy limiting the study of the associations of 
chronic HBV and HCV infection with NHL in this patient group.  
Conclusions: In HIV-infected antiretroviral therapy -treated patients chronic co-infection with HBV and HCV 
is associated with an increased risk of NHL.  
Primary funding source: European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord 
grant agreement n° 260694.  
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Introduction 
In the HIV-negative population, there is growing evidence that chronic hepatitis B virus infection (HBV) and 
hepatitis C virus infection (HCV) are both associated with non-Hodgkin lymphoma (NHL) (1). Mechanisms 
underlying this association remain unclear, but chronic immune activation and B-cell proliferation have been 
postulated as potential mechanisms for both infections (2). HBV DNA has been identified in NHL tumor tissue 
(3), whereas active in vivo HCV replication in lymphocytes has not been consistently found (2). The role of 
chronic co-infection with HBV and HCV in promoting NHL in HIV infection is unclear (4). 
The incidence rate of NHL in HIV-infected individuals is about 10 times higher compared to HIV-negative 
populations (5). NHL is strongly related to compromised immune function or recovery and is an important 
cause of AIDS and death, even in the presence of antiretroviral therapy (ART), accounting for up to one third 
of all AIDS related events (6-8). Some viruses such as Epstein Barr virus and human herpes virus 8 can 
transform lymphocytes in normal or immune compromised hosts and promote the development of NHL such 
as Burkitt’s lymphoma, or primary effusion lymphoma. Growing evidence indicates that some infections 
increase the risk of NHL through chronic immune stimulation in the immune compromised host (9).  
We investigated in a large European multi-cohort study of antiretroviral drug naïve and treated HIV-infected 
individuals whether chronic HBV and HCV infection is associated with an increased risk of NHL.  
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Methods 
The COHERE Collaboration 
We included 18 cohorts with routine data collection for hepatitis B and C co-infection of 33 cohorts from the 
Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) that contributed to the 
2013 COHERE in EuroCoord data merger (http://www.cohere.org; study documents). Data collected included 
information on patient characteristics, ART, CD4 cell count, HIV RNA viral load, co-infection with hepatitis B 
or C, AIDS events, and causes of death. Institutional review board approval was obtained for each 
participating cohort. 
Patients 
Patients were analyzed in two separate periods: (1) when they were ART-naïve; and (2) during ART for those 
who started ART. We included all HIV-infected adults (≥16 years old) who were ART-naïve on January 1st 2000 
or at cohort entry if this was later with at least one measurement for HBV and HCV infection and followed 
them until the date of NHL diagnosis, start of ART, death or the last follow up visit - whichever came first - 
through March 27, 2013. Patients initiating ART (defined as any combination of antiretroviral drugs) were 
followed the same way from the start date of the first ART. We ignored subsequent changes to treatment, 
including discontinuations. All patients with NHL prior to baseline were excluded. Patient visits and 
monitoring frequencies were conducted according to the rules of individual cohorts. 
Exposure Variables and Outcome 
HBV and HCV measurement was not done uniformly but in some cohort at baseline, later during follow-up, 
or from stored samples. Chronic HBV infection was defined as presence of two positive HBV surface antigen 
(HBsAg) measurements more than 6 months apart. HCV infection was defined as having a detectable HCV 
RNA or HCV IgG antibody if HCV RNA was not available.  
If there were no negative HBV or HCV measurements prior to the first positive measurement, we assumed 
the patient had been infected with chronic HBV or HCV since baseline, otherwise the date of the first positive 
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HBsAg or HCV antibody /HCB RNA measurement was the defined start of infection, with individuals assumed 
to be negative for chronic hepatitis B or C until this date. Individuals known to be HBV or HCV negative that 
acquired a new chronic HBV or HCV infection changed their status.  
Our primary outcome was time to the diagnosis of NHL based on the 1993 US Centers for Disease Control 
(CDC) histology criteria (10). We included all subtypes of NHL: Burkitt’s lymphoma (classical or atypical), 
diffuse large B-cell lymphoma (immunoblastic or centroblastic), primary brain lymphoma, and unspecified 
type and death due to NHL based on ICD-10 codings. These endpoints were adjudicated individually in each 
cohort.  
Statistical Analyses 
We approximated a Cox proportional hazards model using a spline-based, parametric survival model, and 
parameterized the log cumulative hazard using cubic splines of time with 5 internal knots at the 5th, 27.5th, 
50th, and 72.5th and 95th percentiles to estimate hazards ratios (HR) and corresponding 95% confidence 
intervals (CI) for the association between chronic HBV and HCV infection and risk of NHL in naïve and ART 
treated patients(11). The exposure to chronic HBV or HCV was time updated, and the following a prior chosen 
baseline covariates were adjusted: age, gender, HIV transmission via intravenous drug use (IDU), CD4 cell 
count and viral load. In a separate model, we further adjusted for time updated CD4 cell count and HIV viral 
load.  
We used inverse probability of censoring weights to adjust for bias due to informative censoring resulting 
from differences between patients continuing to provide measurements over time and those who died, 
started ART or were lost to follow up. A single inverse probability of censoring weight was estimated for each 
patient to account for censoring due to different reasons. The inverse probability of censoring weights were 
estimated by pooled logistic regression using covariates hypothesized to strongly influence censoring: age, 
gender, Caucasian ethnicity, HIV transmission via IDU and cohort at baseline, CD4 cell count and viral load 
both at baseline and time updated (12;13).  
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We next obtained smooth estimates of the cumulative incidence curves stratified by HBV status. These 
estimates for both the HBV positive and HBV negative groups were standardised so that they were adjusted 
to the overall distribution of the characteristics of the entire study population. We then calculated adjusted 
differences in cumulative incidences of NHL using our parametric survival model for HBV positive compared 
to HBV negative individuals at 1, 2, 3, 5, 10 and 12 years. Corresponding 95% CIs were constructed using 
bootstrapping, randomly resampling with replacement 1000 samples of equal size to the original study 
population (Monte Carlo algorithm). Analyses were then repeated for HCV status. 
We investigated the robustness of our results by sensitivity analyses in particular to address survivor bias. 
First, we extended the definition of chronic HBV infection to include patients with single HBsAg 
measurements by combining information from other HBV markers (see Appendix Table 1). Second, if the 
patient had at least one positive HBsAg or HCV-RNA or HCV antibody measurement, we assumed that the 
patient had been chronically infected for the whole follow-up period. Third, if the first HBsAg or HCV 
measurement was positive, we assumed that if the first positive HBsAg or HCV-RNA or HCV antibody 
measurement was less than 6 months after baseline, the patient had been infected since baseline; if the first 
measurement was more than 6 months after baseline and the patient was an injecting drug user, the patient 
had been infected since baseline; in the remaining patients, we reset the baseline to the date of the first 
measurement. Fourth, to control for immortality bias we reassigned baseline to the date of the first available 
HBV or HCV measurement if this was later than the baseline used in the main analyses; (45,107 ART naïve 
and 40,097 ART treated patients were kept in the analyses). Fifth, we removed patients who enrolled into 
cohort before 2000 (35,236 ART naïve and 27,537 ART treated patients were kept in the analyses). Finally, in 
ART-naïve patients we constructed different censoring weights according to different censoring reasons, i.e. 
the start of ART or otherwise. 
We used SAS version 9.2 (SAS Institute Inc., Cary, NC) for analyses, PROC GENMOD for regression analysis, 
and PROC SURVEYSELECT for bootstrapping. We used the stcurve macro in Stata version 14.0 for graphics. 
Role of the Funding Source 
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This study was exclusively funded from governmental grants or foundations with no industry involvement 
e.g. by the European Union Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant 
agreement n° 260694e, funding of the COHERE study group from Agence Nationale de Recherches sur le 
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Results 
Patient Characteristics 
Of 299,690 patients from 33 cohorts, 208,840 patients from 15 cohorts that did not routinely measure HBV 
and HCV markers were excluded from the analyses and a further 36,922 patients were excluded for the 
reasons detailed in Figure 1. 
We included 52,479 ART-naïve patients, of which 40,219 (77%) then went on to start ART. The median follow 
up was 13 (interquartile range [IQR], 2, 41) months for ART naïve and 50 (IQR, 24, 88) months for patients on 
ART. At the time of inclusion into cohorts there were 1339 (2.6%) patients with chronic HBV infection, 7506 
(14.3%) patients with HCV infection (with HCV RNA confirmed in 3807 individuals and missing in the 
remaining) and 210 (0.4%) patients with dual chronic infection. During follow-up an additional 70 and 52 ART 
naïve and 50 and 267 ART treated patients acquired a new chronic HBV and HCV infection. Of HBV-coinfected 
individuals initiating ART, 89% received at least one HBV-active drug including lamivudine, emtricitabine or 
tenofovir. Of HCV co-infected individuals, 1204 (15%) were treated for HCV and 753 (63%) had a sustained 
virological response at week 12.  
Of all included individuals, 22% were females, and 56% of HCV co-infected individuals were injecting drug 
users. Median CD4 cell count in HBV, HCV co-infected and not co-infected patients was 320, 380 and 380 
cells/mm3 at baseline, and 240, 230 and 250 cells/mm3 at initiation of ART, respectively (Table 1). At the time 
of NHL diagnosis median CD4 cell counts were not higher in ART treated HBV and HCV co-infected patients 
than in naïve patients. 
Outcomes in ART Naïve Patients and their Association with Chronic HBV and HCV Infections  
During 115,049 person-years of follow up in ART-naïve individuals, 252 developed NHL. Of those, 47 (18.7%) 
were Burkitt’s lymphoma, 27 (10.7%) diffuse large B-cell lymphoma, 9 (3.6%) primary brain lymphoma, and 
169 (67.1%) were unspecified NHL types. There were 547 deaths with 67 (12.2%) deaths from NHL, and the 
rest being from other causes. Incidence rates of NHL in ART naïve individuals uninfected with HBV and HCV 
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were 186 (95% confidence interval [CI], 180, 193) per 100,000 person-years, while incidence rates were 187 
(95% CI 152, 229), 134 (95% CI 123, 145) and 149 (95% CI 88, 252) per 100,000 person-years in individuals 
with chronic HBV, HCV and dual HBV and HCV infection, respectively. Figure 2 upper part provides survival 
functions for NHL events with or without chronic HBV or HCV in ART naïve individuals. 
Table 2 (upper part) shows the results of multivariate models considering the outcomes of NHL in ART-naïve 
patients. We provide hazard ratios with and without accounting for informative censoring, and with time 
updated adjustment for current CD4 cell count and HIV-1 RNA. In ART-naïve patients, the adjusted hazard 
ratios (with censoring weights applied) for NHL with chronic HBV and HCV infections were 1.33 (95% CI 0.69, 
2.56) and 0.67 (95% CI 0.40, 1.12), respectively. Hazard ratios for NHL in models with time updated CD4 cell 
count and HIV viral load were similar to the ones with adjustment for baseline covariates only. Hazard ratios 
for all baseline covariates included into all models are provided in the web appendix.  
The respective adjusted 5-year risk differences in rates of NHL for naïve individuals was for chronic HBV 1.6 
(95% CI 0.3, 5.9), and for HCV -1.8 (95% CI -6.9, -0.4) cases per 1000 persons (Table 3).  
Outcomes in ART Treated Patients and their Association with Chronic HBV and HCV Infections  
During 191,257 person years of follow-up, 310 ART-treated individuals developed a NHL. Of those, 59 (19.0%) 
were Burkitt’s lymphoma, 33 (10.6%) diffuse large B-cell lymphoma, 20 (6.5%) primary brain lymphoma, and 
198 (63.9%) were unspecified NHL types. There were 1523 deaths with 107 (7.0%) deaths from NHL, and the 
rest being from other causes. Incidence rates of NHL in ART treated individuals were 149 (95% CI 143, 155) 
per 100,000 person years in individuals uninfected with HBV and HCV and 241 (95% CI 198, 293), 200 (95% 
CI 182, 220) and 294 (95% CI 178, 487) per 100,000 person-years in individuals with chronic HBV, HCV and 
dual HBV and HCV infection, respectively. Figure 2 (lower part) provides survival functions for NHL events 
with or without chronic HBV or HCV in ART treated individuals.  
Both chronic HBV and HCV infections were associated with an increased risk of NHL, with an adjusted hazard 
ratio of 1.74 (95% CI, 1.08, 2.82) and 1.73 (95% CI, 1.21, 2.46), respectively (Table 2, lower part). Hazard ratios 
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for NHL in models with time updated CD4 cell count and HIV viral load were also similar to the ones with 
adjustment for baseline covariates only.  
The respective adjusted 5-year risk differences in rates of NHL for ART treated individuals was for chronic 
HBV 5.9 (95% CI 1.8, 14.7), and for HCV 5.4 (95% CI 1.6, 14.6) cases per 1000 persons (Table 3).  
Sensitivity analyses based on different definitions and exposure time to chronic HBV and HCV infections and 
in particular when controlling for immortality bias gave in all models for both naïve and ART treated co-
infected individuals similar hazard ratios for NHL as in the main models specified above.  
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Discussion 
In this multicohort study we found that ART-treated patients with chronic HBV or HCV infection were at 
increased risk for NHL and for the combined endpoint of NHL or death compared to HBV or HCV uninfected 
individuals. Estimates in ART naïve patients were less certain, possibly due to the lower number of events, 
limited follow-up as patients initiated ART or due to other unmeasured competing factors masking the effect 
of chronic HBV and HCV infections in this population. Median CD4 cell count at time of NHL diagnosis in both 
ART naïve and treated HBV and HCV co-infected patients was below 250 cells/mm3 indicating that HBV and 
HCV co-infected patients with NHL initiate ART late, and/or have insufficient HIV viral control and immune 
recovery that may be related to multiple reasons. This unfavourable constellation is aggravated by the fact 
that chronic HBV attenuates immune recovery in individuals treated with ART (14). Whether this is also the 
case for chronic HCV infection is less clear (15;16).  
This study has several limitations. Our analysis is based only on a limited number of cohorts and a fraction of 
patients from COHERE that provided detailed information on chronic HCV and HBV infection. This precluded 
a more powerful analysis for co-infected ART naive patients and may limit the generalizability of our findings. 
The hazard ratios and cumulative incidence functions indicating a protective effect of chronic HCV infection 
in ART naïve individuals are indicative for the competing risk of death from any cause which we found in 
additional analyses (data not shown). Suboptimal screening or data collection for hepatitis co-infections in 
HIV-infected populations is a problem and has been reported in different settings (17). In the different 
cohorts, presence of chronic HCV and HBV infection was not uniformly measured at baseline. However, we 
accounted for these limitations in extensive sensitivity analyses, which all confirmed our findings. Most 
cohorts did not measure or collect HCV RNA to confirm the chronic HCV infection status. HBsAg and HCV 
clearance are not routinely measured in all cohorts. HBV DNA in ART treated patients and HCV RNA clearance 
following treatment are not routinely monitored or might have been underreported. A substantial proportion 
of ART treated HBV co-infected patients continue to express HBV DNA and some patients might experience 
relapses (18). HBV reactivation in the presence of ART in severely immunosuppressed patients or HBV 
resistance to lamivudine might be possible explanations for the observed increased risk of NHL in co-infected 
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patients (19). Continued immune stimulation following antiviral treatment against HBV and HIV in co-infected 
patients might be another mechanism, given that chronic B cell stimulation by HBsAg continues to persist 
despite inhibition of viral replication by antiviral therapy and indirect effects mediated by increased pro-
inflammatory cytokine expression and secretion in these patients may also contribute to lymphomagenesis 
(20-22). Only a limited number of cohorts routinely test HCV and HBV negative patients for incident infections 
or HCV re-infection following successful treatment (23;24). All these deficiencies will introduce 
misclassification biases, the direction of the bias, however, is in all instances conservative and will 
underestimate the true association of HCV and HBV co-infection and NHL in ART naïve or treated patients. A 
large number of NHL types were not classified and therefore all NHL cases had to be coalesced, which 
precluded an analysis according to NHL subtypes. In addition, ascertainment of NHL was not uniformly 
reported by all cohorts. As a consequence, our findings might not accurately reflect the prognosis of chronic 
HCV and HBV co-infection relevant for different types of NHL. Better screening and reporting of chronic HBV 
and HCV is needed in addition to more detailed data on NHL subtypes.  
To our knowledge this is the first large prospective cohort study indicating an association between chronic 
HBV and HCV infection and NHL in HIV co-infected individuals. Previous studies not confirming such an 
association were smaller cohort or case control studies (4;25). Incidence rates for NHL in ART treated 
compared to naïve patients were not remarkably different in both chronic HBV and HCV infection. This might 
at least partially be attributed to cases of unmasking NHL in the context of immune reconstitution syndrome 
when patients, as in our study population, initiate ART at low CD4 cell count (26;27). HBV and HCV co-infected 
patients are more likely to die from other causes, due to injecting drug use or other epidemiological 
differences impacting on mortality. Therefore, to adjust for bias due to informative censoring we used inverse 
probability of censoring weights.  
Several meta-analyses of observational studies have investigated the association between chronic HBV and 
HCV infection in HIV uninfected individuals. The pooled odds ratios for chronic HBV infection and NHL in 5 
cohort and 17 case control studies were 2.06 (95% CI 1.44–2.95) and 2.27 (CI 1.74–2.94) respectively, but 
heterogeneity for both estimates was moderate to high (28). The association could be confirmed for studies 
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conducted in high and low prevalence areas and in a subset of studies for the diffuse large cell lymphoma 
NHL subtype. In a later published nationwide study from Sweden not included into the meta-analysis 
individuals with a chronic HBV infection showed an increased standardized incidence ratio of 4.89 (95%CI 
3.81-6.18) for NHL (29). Incidence rates for NHL of HBV co-infected individuals from our study indicate that 
the risk for NHL is – irrespective of antiretroviral therapy – about 10 times higher in the presence of HIV than 
in HBV mono-infected individuals (30). 
In a meta-analysis of 15 case control and two cohort studies in HIV uninfected individuals the pooled odds 
ratio for chronic HCV infection and NHL were 2.5 (95% CI, 2.1-3.1) and 2.0 (95% CI, 1.8-2.2) respectively, 
with high heterogeneity between case controls study findings (1). Diffuse large B-cell lymphoma and 
marginal zone lymphoma are NHL types most frequently associated with HCV. Several pathogenic 
mechanisms have been suggested for explaining this association (31). Studies showing regression of B-cell 
NHL following HCV eradication represent a strong argument in favour of a causal relationship between HCV 
infection and these types of NHL (32). In HIV infection, B-cell type NHL, in particular diffuse large cell 
subtypes represent the majority of NHL, which is in line with a potential contribution of HCV to the 
pathogenesis of NHL. Due to the large number of uncharacterized NHL this study, however, lacks the power 
to detect an association of HCV with specific subtypes. Nonetheless, our findings do suggest that chronic 
HCV co-infection, along with immune suppression may represent a relevant cause for the increased 
incidence of NHL observed in persons living with HIV.  
In conclusion, ART treated patients with chronic HBV and HCV co-infection are at increased risk of NHL, the 
currently most frequent occurring AIDS defining condition. Our study was not sufficiently powered to show 
such an association in ART naïve co-infected patients. Early diagnosis and treatment of HIV in conjunction 
with routine screening for chronic HBV and HCV infection is indispensable to further lower NHL morbidity 
and mortality in HIV-infected individuals. Uptake of treatment for chronic HCV infection in co-infected 
patients in Europe has been low and, due to peg-interferon and ribavirin based regimen related high failure 
and toxicity rates, mainly limited to patients with higher CD4 cell count (above 350 cells/mm3) and advanced 
liver fibrosis and high costs of direct acting antiviral drugs (33-36). Our findings provide a strong case that 
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HCV co-infected patients with poor immune status or restoration (CD4 cell count below 250 cells/mm3) 
represent a population at high risk of NHL and death and deserve high priority for access to well tolerated 
interferon-free direct acting antiviral treatment programs similar to patients with advanced liver fibrosis or 
liver cirrhosis.  
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Figure 1: Patient flow for the selection of the study population. 
COHERE Collaboration of Observational HIV Epidemiological Research Europe, HBV hepatitis B virus, HCV 
hepatitis C virus, NHL non-Hodgkin lymphoma 
 
Figure 2: Non-Hodgkin lymphoma event-free survival in antiretroviral therapy (ART)-naïve and ART treated 
HIV infected patients by chronic hepatitis B and hepatitis C status at baseline 
 
ART antiretroviral therapy, HBV hepatitis B virus, HCV hepatitis C virus  
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